How Drug Prices Are Set in the United States

The Same Pill. Radically Different Prices Around the World.

Americans pay, on average, 2.56 times more for prescription drugs than residents of 32 other high-income countries, according to a 2021 RAND Corporation analysis. For brand-name drugs specifically, the ratio reaches 3.44 times. A month's supply of the cancer drug imatinib (Gleevec) costs approximately $10,000 in the United States; the same drug costs roughly $2,700 in Canada and $1,000 in the United Kingdom. These disparities exist not because American pharmaceutical companies spend more on research and development per drug—studies have repeatedly failed to establish a clean link between price levels and R&D investment—but because the United States is the only high-income country that does not systematically negotiate or regulate drug prices at the national level. What exists instead is a layered system of private negotiations, rebates, and intermediary markup that makes American drug pricing among the most opaque in the world.

No single entity sets the price. Several determine it.

The Price Stack: From WAC to What You Pay

Understanding drug prices requires distinguishing among several different "prices" that exist simultaneously for the same drug:

The gap between WAC and net price has grown dramatically. For brand-name drugs, the average rebate as a percentage of WAC exceeded 50% by 2022, according to the USC Schaeffer Center. A drug with a $100 WAC might carry a $50 net price—but patient cost-sharing is typically calculated on the WAC, not the net price, meaning patients often pay more than the manufacturer actually receives.

Pharmacy Benefit Managers and the Rebate System

Pharmacy Benefit Managers (PBMs) are the central intermediaries in the drug pricing system, managing prescription drug benefits on behalf of insurers, employers, and government programs. The three largest PBMs—CVS Caremark, Express Scripts (Cigna), and OptumRx (UnitedHealth Group)—manage approximately 80% of U.S. prescription drug transactions.

PBMs negotiate rebates from drug manufacturers in exchange for favorable formulary placement—placing a drug on a lower cost-sharing tier where patients are more likely to fill it. The rebate is paid by the manufacturer to the PBM; the PBM retains a portion and passes the remainder to the plan sponsor. The exact split between PBM retention and plan pass-through is typically confidential.

Critics argue that the rebate system distorts drug pricing by incentivizing manufacturers to set artificially high list prices (to allow room for large rebates while maintaining net revenue) and creating a conflict of interest for PBMs (who may favor high-rebate drugs over lower-cost alternatives that would better serve patients). PBMs counter that rebates lower net costs for payers and that transparency in rebate arrangements exists through contractual terms.

Formulary Tier Placement and Cost-Sharing

Every Part D and commercial drug plan organizes its covered medications into tiers, with patient cost-sharing increasing as tier number rises. A typical structure:

• Tier 1: Preferred generics — lowest copay ($0–$5)
• Tier 2: Non-preferred generics — low copay ($10–$20)
• Tier 3: Preferred brand drugs — moderate copay ($40–$60)
• Tier 4: Non-preferred brand drugs — high copay ($80–$100+)
• Tier 5: Specialty drugs — coinsurance (often 25–33% of drug cost)

Formulary placement directly affects which drug a patient fills. A drug without formulary coverage requires prior authorization, a formulary exception, or full out-of-pocket payment. The manufacturer's rebate strategy fundamentally determines whether they achieve preferred tier placement.

The 340B Drug Pricing Program

The 340B Drug Pricing Program, created in 1992, requires pharmaceutical manufacturers participating in Medicaid to provide outpatient drugs to certain safety-net healthcare providers at significantly reduced prices—typically 25–50% below WAC. Eligible entities ("covered entities") include federally qualified health centers, Ryan White HIV/AIDS clinics, disproportionate share hospitals, and similar providers serving low-income populations.

The program has grown substantially: 340B covered entity purchases totaled approximately $44 billion in 2021. Critics allege that many hospitals use 340B purchasing for commercially insured patients and retain the spread as revenue rather than using savings to benefit low-income patients. Pharmaceutical manufacturers have attempted to restrict contract pharmacy arrangements used in 340B, sparking significant litigation. The program's scope and administration remain intensely contested.

The IRA's Medicare Drug Negotiation: A Historic Change

The Inflation Reduction Act of 2022 gave CMS the authority to negotiate drug prices directly with manufacturers for Medicare—the first time in the program's history that direct negotiation has been authorized. The first 10 drugs subject to negotiated prices were announced in 2023, with the negotiated prices taking effect in 2026. Drugs selected were high-spend, single-source drugs without generic competition, including blood thinners, diabetes medications, and heart failure drugs.

The negotiated prices represent reductions of 38–79% off list prices for the first cohort. Manufacturers challenged the program in multiple federal lawsuits, arguing that the negotiation process constitutes compelled speech and unconstitutional taking; courts have thus far ruled against the manufacturers on these arguments.

International Price Comparison

Patent Cliffs, Generics, and Biosimilar Barriers

When a brand-name drug's patent expires, generic manufacturers may enter the market with copies at dramatically lower prices—often 80–90% below brand price within two years of generic entry. Manufacturers have developed strategies to extend market exclusivity beyond patent expiration, including "product hopping" (making minor reformulations to extend patents), "pay-for-delay" settlements with generic manufacturers (restricting but not banning them by the FTC v. Actavis 2013 ruling), and obtaining additional patents on delivery mechanisms or manufacturing processes.

Biologics—drugs derived from living cells—face a different dynamic. The FDA's biosimilar approval pathway has produced substantially lower uptake in the U.S. than in Europe, where biosimilar market shares commonly exceed 70–80% for eligible drugs. In the U.S., PBM rebate contracts that favor the originator biologic over its biosimilar competitors have been identified as a significant barrier to biosimilar adoption, a dynamic visible in the slow market penetration of Humira biosimilars despite their FDA approval.